Joshua A.

Hill

MD

related links

bio

Dr. Joshua A. Hill is an Assistant Professor at the Fred Hutchinson Cancer Center and Associate Professor at the University of Washington (UW). His research program is focused on clinical and translational studies to improve preventive and treatment strategies for infections in patients receiving hematopoietic cell transplantations (HCT) and CAR-T cell therapies. Dr. Hill trained in Transplant Infectious Diseases at Fred Hutch and epidemiology/biostatics at the Harvard School of Public Health. He serves as an attending physician on the Immunocompromised Host Infectious Diseases Service at Fred Hutch and UW Medical Center.

research interests

My research focuses on clinical and translational investigations relating to infections in immunocompromised hosts, with a focus on disease associations, risk stratification, and diagnostic strategies for viral infections in transplant recipients. My interest in infections in immunocompromised hosts stems from my experiences as a clinician, where I witness the impact of these pathogens in vulnerable populations. I have translated this interest into clinical and translational research projects focused on investigations of risk factors for and disease associations with human herpesvirus 6 (HHV-6) and other viruses that affect immunocompromised patients. I am also involved in clinical trials for drug and vaccine development to treat infections in this patient population.

clinical interests

I specialize in the treatment of infectious diseases in cancer patients, solid organ transplant patients, and other immunocompromised patients with a particular interest in viral infections. 

education & training

Education

2001-2005: BA, Plan II Honors Program & Dean’s Scholars Program, summa cum laude, University of Texas at Austin, Austin, TX, September 2001 – May 2005       

2005-2009: MD, summa cum laude, University of Texas Southwestern Medical Center, Dallas, TX, August 2005 – June 2009

Training

2009-2012: Resident in Internal Medicine, Brigham and Women’s Hospital/Harvard, Boston, MA

2012-2014: Fellow in Infectious Diseases, University of Washington, Seattle, WA

2014: Summer Program in Clinical Effectiveness Research, Epidemiology, and Biostatistics, Harvard School of Public Health, Boston, MA

2014-2015: Fellow, Transplant Infectious Diseases, Fred Hutchinson Cancer Center, Seattle, WA

honors

2007-2009: Scholarship for Excellence in Academics, Leadership, and Service, University of Texas Southwestern Medical School, Dallas, TX

2007-2009: Alpha Omega Alpha Honor Society, Junior and Senior Member

2012: George Santos Award for Best Clinical Science Article by a New Investigator, American Society for Blood and Marrow Transplantation (ASBMT)

2014-2015: Joel Meyers Infectious Diseases Scholar, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA

2014-2016: Robert A. Good New Investigator Award, ASBMT

2015: ASBMT Clinical Research Training Course Scholar

2015: Caroline B. Hall Young Investigator Award, HHV-6 Foundation

2015-2021: NIH Clinical Loan Repayment Program Award and Renewal x 2

2018-2021: Amy Strelzer Manasevit Research Program Scholar Award, NMDP/ASBMT

2021: Fialkow Scholar Award, Department of Medicine, University of Washington

2021: Fellow, Infectious Diseases Society of America

publications

Hill JA, Mayer BT, Xie H, Leisenring WM, Huang M-L, Stevens-Ayers T, Milano F, Delaney C, Sorror ML, Sandmaier BM, Nichols G, Zerr DM, Jerome KR, Schiffer JT, Boeckh M. The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality. Blood. 2017; 129(16), 2316-2325. PMCID: PMC5399484 [original work]

This article was selected for ‘This Week in Blood’, a weekly snapshot of the hottest studies from each week’s issue of Blood.                        PubMed Abstract

Hill JA, Li D, Hay KA, Green ML, Cherian S, Chen X, Riddell SR, Maloney DG, Boeckh M, Turtle CJ. Infectious Complications of CD19-Targeted Chimeric Antigen Receptor-Modified T Cell Immunotherapy. Blood. 2018 Jan; 131(1):121-130. PMCID: PMC5755046 [original work]

This article was selected for ‘This Week in Blood’, a weekly snapshot of the hottest studies from each week’s issue of Blood. This article was accompanied by an editorial, PMID 29301772.                              PubMed Abstract                             

Hill JA, Vande Vusse LK, Xie H, Chung EL, Yeung C, Seo S, Stevens-Ayers T, Fisher CE, Huang M-L, Stewart FM, Jerome KR, Zerr DM, Corey L, Leisenring WM, Boeckh M. Human Herpesvirus 6B and Lower Respiratory Tract Disease after Hematopoietic Cell Transplantation. J Clinical Oncol. 2019 Oct 10; 37(29):2670-2681. PMID 31449472. PMCID: PMC7351330 [original work].                        FredHutch

Walti CS, Krantz EM, Maalouf J, Boonyaratanakornkit J, Keane-Candib J, Joncas-Schronce L, Stevens-Ayers T, Dasgupta S, Taylor JJ, Hirayama AV, Bar M, Gardner RA, Cowan AJ, Green DJ, Boeckh MJ, Maloney DG, Turtle CJ, Hill JA. Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies. JCI Insight. 2021 8; 6(11). PMID: 33914708. PMCID: PMC8262349. [original work]

This article was selected for ‘JCI This Month’, a monthly print digest of the JCI and JCI Insight journals.                                                        JCI Insight

Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, Oguchi G, Ryan P, Nielsen BU, Brown M, Hidalgo A, Sachdeva Y, Mittal S, Osiyemi O, Skarbinski J, Juneja K, Hyland RH, Osinusi A, Chen S, Camus G, Abdelghany M, Davies S, Behenna-Renton N, Duff F, Marty FM, Katz MJ, Ginde AA, Brown SM, Schiffer JT, Hill JA. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med. 2021 Dec 22, PMID: 34937145. [original work]

This article was accompanied by an editorial: PMID 34936760 in addition to an audio interview with the editors of the NEJM: PMID 34936745.                                                                                              PubMed Abstract